Pulse Biosciences Announces Organizational Realignment to Accelerate Cardiac Catheter Program

Pulse Biosciences, Inc. is undergoing an organizational realignment to intensify its focus on developing its nsPFA electrophysiology catheters and cardiac devices for atrial fibrillation (AFib) treatment. This strategic shift follows the release of promising clinical data from a feasibility study of their nPulse Cardiac Catheter System. The realignment will involve a reduction in sales and marketing staff while bolstering product development functions. The company highlighted strong clinical outcomes from a 150-patient European feasibility study, showing high procedural success rates and durable efficacy in treating AFib. They are reallocating resources to prioritize the catheter program, including an upcoming pivotal IDE study in the US and Europe, while calibrating investments in surgical programs and streamlining operations for their soft-tissue ablation system. Pulse Biosciences aims to leverage these advancements to potentially offer a best-in-class solution for AFib treatment.